Publications

ECCMID

Copenhagen | April 2023

• All-cause and attributable mortality in invasive candidiasis and/or candidaemia with rezafungin and caspofungin treatment: outcomes from the ReSTORE trial [Presentation] [04732]
• Safety outcomes with rezafungin and caspofungin in the treatment of candidaemia and/or invasive candidiasis: Phase 3 data from the ReSTORE trial [P2061] [04525]
• Rezafungin Activity against Candida and Aspergillus Isolates Causing Invasive Infections in European Medical Centres (2019–2021) [P508] [00508]
• Rezafungin Activity against Candidemia isolates collected from European medical centres (2019–2021) [P509] [00509]
• Rezafungin and caspofungin treatment response in candidaemia/invasive candidiasis by baseline Candidaspecies: Analysis of pooled Phase 2 and Phase 3 results [P2048] [04353]
• Treatment outcomes in candidaemia and/or invasive candidiasis among patients receiving rezafungin or caspofungin while the fungal culture was still positive [P2063] [04913]
• Treatment outcomes with rezafungin and caspofungin in people aged 65 years and above with candidaemia and/or invasive candidiasis: Integrated analysis of pooled Phase 2 and Phase 3 data [03861] [ePoster]
• First case of Candida glabrata prosthetic knee infection treated with rezafungin: case report [P3398]

IDWEEK

Washington, D.C. – Virtual Hybrid | October 2022

• Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis [231]
• Assessment of The Proportion of Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received an Echinocandin (EC) and Were Potentially Eligible for an Earlier Hospital Discharge (HD) [468]
• Healthcare Resource Utilization (HRU) among Hospitalized Patients (Pts) with Candidemia (C) and Invasive Candidiasis without Candidemia (IC) Who Received Definitive Treatment with an Echinocandin (EC) Across United States (US) Hospitals [469]
• Impact of Elevated MIC Values on Echinocandin Pharmacokinetic-Pharmacodynamic (PK-PD) Candida glabrata Target Attainment (TA) [592]
• Coadministration of Rezafungin Does Not Impact the Pharmacokinetics of Cyclosporine, Ibrutinib, Mycophenolate Mofetil, or Venetoclax [1694]
• Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021 [1731]
• New Antimicrobials and ID Diagnostics in the Pipeline – Fungal
  Presenter: Taylor Sandison, M.D., MPH, Cidara

SSAI & ICHS Joint Meeting

Basel, Switzerland | September 2022

• Rezafungin Treatment of Candidemia and Invasive Candidiasis: Outcomes Stratified by Baseline Renal Function – Analysis of the Phase 2 + Phase 3 Trials [P13]
• Rezafungin Efficacy and Safety in Immunocompromised Patients: Subanalyses of the Phase 3 Trial in the Treatment of Candidemia and Invasive Candidiasis [P38]
• Rezafungin In Vitro Activity against Candida spp. Causing Invasive Infections in Hematology/Oncology and Transplant Units Worldwide (2014–2021) [P54]

ECCMID

Lisbon – Virtual Hybrid | April 2022

• ReSTORE: Efficacy and Safety Results of the Phase 3, Noninferiority Trial of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis [Poster] [ePoster slides]
• Patient-level Meta-Analysis of Efficacy and Safety from STRIVE and ReSTORE: Randomized, Double-blinded, Multicenter Phase 2 and Phase 3 Trials of Rezafungin in the Treatment of Candidemia and/or Invasive Candidiasis [Presentation]
• Venetoclax and Ibrutinib Pharmacokinetics Unaltered when Coadministered with Rezafungin [Presentation]

EBMT

Virtual | March 2022

• Coadministration of Rezafungin Does Not Impact Cyclosporine or Mycophenolate Mofetil Pharmacokinetics [P692]

TIMM

Virtual | October 2021

• Rezafungin safety and pharmacokinetics in subjects with moderate or severe hepatic impairment [335]
• Evaluation of the post-antifungal effect of rezafungin and micafungin against Candida albicans, Candida parapsilosis, and Candida glabrata [388]

IDWeek

Virtual | Sep-Oct 2021

• A Multicenter, Mixed-Method Evaluation of Delayed Hospital Discharge in Patients with Invasive Candidiasis Receiving Echinocandins [157]
• Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin [982]
• Activity of Rezafungin and Comparator Antifungal Agents Tested Against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019–2020) [1076]

ISICEM

Virtual | August 2021

• Early outcomes and intensive care unit length of stay with rezafungin once-weekly echinocandin in invasive Candida disease [P038]

ISHAM-Asia

Virtual | August 2021

• Activity of Rezafungin against Clinical Candida and Aspergillus spp. Isolates Collected in Asia-Pacific Countries (2014-2018) [ABST60]
• Rezafungin: A novel, once-weekly echinocandin in phase 3 development for treatment and prevention of invasive fungal disease [symposium presentation]

ECCMID

Virtual | July 2021

• Development and validation of a modified EUCAST yeast broth microdilution MIC method for rezafungin to mitigate nonspecific binding through incorporation of Tween 20 [01052]
• Analysis of Safety from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Assessment of Adverse Events and Laboratory Values [01672]
• Analysis of Efficacy from STRIVE Phase 2 Trial of Rezafungin Treatment of Candidemia and/or Invasive Candidiasis: Outcomes During Initial Days of Treatment [01677]
• A Multicenter Pharmacoepidemiologic Evaluation of Echinocandin Use [02816]

ICHS SYMPOSIUM

VIRTUAL | February 2021

• Efficacy and Safety By Renal Function in the Phase 2 STRIVE Trial of Rezafungin in Treatment of Candidemia and Invasive Candidiasis (IC) [Poster]
• Safety and Efficacy of Rezafungin in Immunocompromised Patients: Analysis of Outcomes from the Phase 2 STRIVE Trial of Rezafungin for Treatment of Candidemia and Invasive Candidiasis [Poster]
• Fungal Eradication With Extended Rezafungin Treatment In a Murine Model Of Pneumocystis Pneumonia [Poster]
• Rezafungin: Evidence and Experience to Date [Industry Symposium Presentation]

SCCM

VIRTUAL | January 2021

• Effect of Moderate Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin

ESICM LIVES

VIRTUAL | December 2020

• Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin: Outcomes by ICU Status and APACHE II Score
• Analysis of Outcomes by Geographic Region of Enrollment in STRIVE, the Phase 2 of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis (IC) [encore]
• Analysis of the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin: Outcomes by Body Mass Index (BMI) [encore]

IDWeek

VIRTUAL | October 2020

• Outcomes by Body Mass Index (BMI) in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin [637]
• Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations [1174]
• Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin [1284]
• Pharmacokinetics, Excretion, and Mass Balance of [14C]-Rezafungin Following Intravenous (IV) Administration in Healthy Adults [1286]

ACCP

VIRTUAL | October 2020

• Phase 2 STRIVE Clinical Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrates Consistent Trough Concentrations Across Diverse Patient Populations [55655-Encore]
• Pharmacoepidemiologic Evaluation of Echinocandin Use [55660-Encore]

Absence of Clinically Meaningful Drug-Drug Interactions with Rezafungin: Outcome of Investigations | Antimicrobial Chemotherapy | May 2023

Successful expanded access use of rezafungin, a novel echinocandin, to eradicate refractory invasive candidiasis in a liver transplant recipient | J Antimicrob Chemother | Jun 2022

Evaluation of Rezafungin Provisional CLSI Clinical Breakpoints and Epidemiological Cutoff Values Tested against a Worldwide Collection of Contemporaneous Invasive Fungal Isolates (2019 to 2020) | J Clin Microbiol | Apr 2022 | Vol 60, Issue 4

Metabolism, Excretion, and Mass Balance of [¹⁴C]-Rezafungin in Animals and Humans | Antimicrob Agents Chemother | January 2022 | Vol 66, Issue 1

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections | Antimicrob Agents Chemother | October 2021 | Vol 65, Issue 11

The long-acting echinocandin, rezafungin, prevents Pneumocystis pneumonia and eliminates Pneumocystis from the lungs in prophylaxis and murine treatment models | J Fungi | September 2021 | Vol 7, Issue 9

Expanded access use of rezafungin for salvage therapy of invasive Candida glabrata infection: A case report | Open Forum Infect Dis | August 2021 | Vol 8, Issue 11

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum | Microorganisms | April 2021 | Vol 9, Issue 4

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia | Antimicrob Agents Chemother | February 2021 | Vol 65, Issue 3

Rezafungin: a novel antifungal for the treatment of invasive candidiasis | Future Microbiol | January 2021 | Vol 16, Issue 1

Rezafungin versus Caspofungin in a Phase 2, Randomized, Double-Blind Study for the Treatment of Candidemia and Invasive Candidiasis – The STRIVE Trial | Clin Infect Dis | September 2020

• Erratum | Clin Infect Dis | June 2021 | Vol 73, Issue 3

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species | J Fungi | August 2020 | Vol 6, Issue 3

Activity of a Long-Acting Echinocandin, Rezafungin, and Comparator Antifungal Agents Tested against Contemporary Invasive Fungal Isolates (SENTRY Program, 2016 to 2018) | Antimicrob Agents Chemother | April 2020 | Vol 64, Issue 4

Rezafungin In Vitro Activity against Contemporary Clinical Nordic Candida Isolates and Candida auris Determined by the EUCAST Reference Method | Antimicrob Agents Chemother | April 2020 | Vol 64, Issue 4

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae | J Antimicrob Chemother | December 2019 | Vol 74, Issue 12

Lack of Effect of Rezafungin on QT/QTc Interval in Healthy Subjects | Clin Pharmacol Drug Dev | December 2019 | Vol 9, Issue 4

Rezafungin Treatment in Mouse Models of Invasive-Candidiasis and Aspergillosis: Insights on the PK/PD Pharmacometrics of Rezafungin Efficacy | Pharmacol Res Perspect | December 2019 | Vol 7, Issue 6

Determination of Pharmacodynamic Target Exposures for Rezafungin against Candida tropicalis and Candida dubliniensis in the Neutropenic Mouse Disseminated Candidiasis Model | Antimicrob Agents Chemother | November 2019 | Vol 63, Issue 11

Extended-Interval Dosing of Rezafungin against Azole-Resistant Aspergillus fumigatus | Antimicrob Agents Chemother | October 2019 | Vol 63, Issue 10

Pharmacodynamic Evaluation of Rezafungin (CD101) Against Candida auris in the Neutropenic Mouse Invasive-Candidiasis Model Antimicrob Agents Chemother | November 2018 | Vol 62, Issue 11

Rezafungin (CD101) demonstrates potent in vitro activity against Aspergillus, including azole-resistant Aspergillus fumigatus isolates and cryptic species November 2018 | Vol 73, Issue 11

Rezafungin (CD101), a Next Generation Echinocandin. a Systematic Literature Review and Assessment of Possible Place in Therapy J Glob Antimicrob Resist | September 2018 | Vol 14

EUCAST reference testing of rezafungin susceptibility: impact of choice of plastic plates Antimicrob Agents Chemother | September 2019 | Vol 63, Issue 9

Evaluation of the Efficacy of Rezafungin, a Novel Echinocandin, in the Treatment of Disseminated Candida auris Infection Using an Immunocompromised Mouse Model J Antimicrob Chemother | August 2018 | Vol 73, Issue 8

Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 Data Antimicrob Agents Chemother | June 2018 | Vol 62, Issue 6

Overcoming the Resistance Hurdle: PK-PD Target Attainment Analyses of Rezafungin (CD101) for Candida albicans and Candida glabrata Antimicrob Agents Chemother | June 2018 | Vol 62, Issue 6

Ex vivo Rezafungin Adsorption and Clearance During Continuous Renal Replacement Therapy Blood Purif | June 2018 | Vol 46, Issue 3

Activity of CD101, a Long-Acting Echinocandin, Against Clinical Isolates of Candida auris Diag Microbiol Infect Dis | March 2018 | Vol 90, Issue 3

Pharmacodynamics of the Long Acting Echinocandin, CD101, in the Neutropenic Invasive-Candidiasis Murine Model Using an Extended-Interval Dosing Design Antimicrob Agents Chemother | February 2018 | Vol 62, Issue 2

CD101, a Novel Echinocandin Possesses Potent Anti -Biofilm Activity Against Early and Mature Candida albicans Biofilms Antimicrob Agents Chemother | February 2018 | Vol 62, Issue 2

The Future of Echinocandin Therapy J Antimicrob Chemother | January 2018 | Vol 73, Issue Suppl 1

In Vitro Potency and Fungicidal Activity of CD101, a Novel Echinocandin, Against Recent Clinical Isolates of Candida Spp. Diag Microbiol Infect Dis | November 2017 | Volume 89, Issue 3

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters Antimicrob Agents Chemother | November 2017 | Vol 61, Issue 11

Unraveling Drug Penetration of Echinocandin Antifungals at the Site of Infection in an Intra-Abdominal Abscess Model Antimicrob Agents Chemother | October 2017 | Vol 61, Issue 10

CD101, a Long-Acting Echinocandin, and Comparator Antifungal Agents Tested Against a Global Collection of Invasive Fungal Isolates in the SENTRY 2015 Antifungal Surveillance Program Int J Antimicrob Agents | September 2017 | Vol 50, Issue 3

Pharmacokinetics of the Novel Echinocandin, CD101, in Multiple Animal Species Antimicrob Agents Chemother | April 2017 | Volume 61, Issue 4

Activity of a Long-Acting Echinocandin (CD101) and Seven Comparator Antifungal Agents Tested Against a Global Collection of Contemporary Invasive Fungal Isolates in the SENTRY (2014) Antifungal Surveillance Program Antimicrob Agents Chemother | March 2017 | Volume 61, Issue 3

CD101, a Novel Echinocandin With Exceptional Stability Properties and Enhanced Aqueous Solubility J Antibiotics | February 2017 | Volume 70, Issue 2

Structure-Activity Relationships of a Series of Echinocandins and the Discovery of CD101, a Highly Stable and Soluble Echinocandin With Distinctive Pharmacokinetic Properties  Antimicrob Agents Chemother | February 2017 | Volume 61, Issue 2

Safety and Pharmacokinetics of CD101 IV, a Novel Echinocandin, in Healthy Adults  Antimicrob Agents Chemother | February 2017 | Volume 61, Issue 2

Preclinical Evaluation of the Stability, Safety and Efficacy of CD101, a Novel Echinocandin Antimicrob Agents Chemother | November 2016 | Volume 60, Issue 11

Activity of a Long-Acting Echinocandin, CD101, Determined Using CLSI and EUCAST Reference Methods, Against Candida and Aspergillus Spp., Including Echinocandin- and Azole-Resistant Isolates J Antimicrob Chemother | October 2016 | Volume 71, Issue 10

Characterization of in Vitro Resistance Development to the Novel Echinocandin, CD101, in Candida Species Antimicrob Agents Chemother | September 2016 | Volume 60, Issue 10

CD101: a Novel Long-Acting Echinocandin Cell Microbio | September 2016 | Volume 18, Issue 9